Amneal Pharmaceuticals, Inc. operates through three primary business segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment focuses on the development and commercialization of complex generics, injectables, and biosimilars. The Specialty segment provides proprietary branded pharmaceutical products, primarily targeting central nervous system conditions such as Parkinson's disease and migraine, as well as endocrine disorders. Through its AvKARE segment, the company distributes pharmaceuticals and medical products to U.S. federal government agencies, retail pharmacies, and institutional customers. While primarily focused on the U.S. market, Amneal maintains a global footprint with research and manufacturing facilities in the United States, Ireland, and India. The company has grown significantly through organic research and development as well as strategic acquisitions, positioning itself as a major supplier in the U.S. generic drug market.
